|
| 37821242 | PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. | Eur Urol Oncol | 2024 |
| 36269935 | Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials. | J Clin Oncol | 2023 |
| 37808453 | ESTRO ACROP consensus recommendation on the target volume definition for radiation therapy of macroscopic prostate cancer recurrences after radical prostatectomy. | Clin Transl Radiat Oncol | 2023 |
| 37627187 | Node Oligorecurrence in Prostate Cancer: A Challenge. | Cancers (Basel) | 2023 |
| 37639648 | Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate. | J Clin Oncol | 2023 |
| 37251620 | ESTROÂ ACROP guideline on prostate bed delineation for postoperative radiotherapy in prostate cancer. | Clin Transl Radiat Oncol | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 36858728 | Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. | Lancet Oncol | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 34538073 | MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial. | Br J Radiol | 2022 |
| 35476942 | Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial. | Radiother Oncol | 2022 |
| 35440417 | Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. | Eur Urol | 2022 |
| 35469702 | High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium. | Eur Urol | 2022 |
| 35427469 | High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial. | Lancet Oncol | 2022 |
| 35450732 | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. | Eur Urol | 2022 |
| 36228761 | Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus. | Radiother Oncol | 2022 |
| 36010964 | Advances in Transversal Topics Applicable to the Care of Bladder Cancer Patients in the Real-World Setting. | Cancers (Basel) | 2022 |
| 36115773 | Reply to Leonard P. Bokhorst and Berdine L. Heesterman's Words of Wisdom re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial. Eur Urol. 2022;82:441. | Eur Urol | 2022 |
| 35101463 | Testosterone levels and testosterone kinetics: The importance of its clinical significance. | Radiother Oncol | 2022 |
| 35051385 | Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. | Lancet Oncol | 2022 |
| 35050303 | Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. | JAMA Oncol | 2022 |
| 33386290 | The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases. | Eur Urol Focus | 2021 |
| 33913091 | Dosimetric impact of rectum and bladder anatomy and intrafractional prostate motion on hypofractionated prostate radiation therapy. | Clin Transl Oncol | 2021 |
| 34563208 | Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the Expanded Prostate Cancer Index Composite for Clinical Practice in Spain. | Health Qual Life Outcomes | 2021 |
| 33964325 | Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial. | Radiother Oncol | 2021 |
| 32487218 | Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study. | Radiat Oncol | 2020 |
| 32001144 | Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. | Eur Urol | 2020 |
| 30328558 | Impact of rectum and bladder anatomy in intrafractional prostate motion during hypofractionated radiation therapy. | Clin Transl Oncol | 2019 |
| 31570236 | Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy. | Radiother Oncol | 2019 |
| 30784712 | author reply. | Urology | 2019 |
| 30293231 | Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology. | Clin Transl Oncol | 2019 |
| 30266376 | Long-term Outcomes and Patterns of Failure Following Trimodality Treatment With Bladder Preservation for Invasive Bladder Cancer. | Urology | 2019 |
| 30617939 | Survival after biochemical failure in prostate cancer treated with radiotherapy: Spanish Registry of Prostate Cancer (RECAP) database outcomes. | Clin Transl Oncol | 2019 |
| 28374321 | Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer. | Clin Transl Oncol | 2017 |
| 28105537 | Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consensus between scientific societies. | Clin Transl Oncol | 2017 |
| 28299579 | Erratum to: Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consensus between scientific societies. | Clin Transl Oncol | 2017 |
| 26900365 | Corrigendum to "Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance". [Rep. Pract. Oncol. Radiother. 20 (2015) 259-272]. | Rep Pract Oncol Radiother | 2016 |
| 26621508 | Management of prostate cancer patients following radiation therapy after radical surgery referred from urology to radiation oncology departments in Spain. | Clin Transl Oncol | 2016 |
| 27598804 | Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer:Â Results From the DART 01/05 Randomized Phase 3 Trial. | Int J Radiat Oncol Biol Phys | 2016 |
| 25183050 | Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies. | Clin Transl Oncol | 2015 |
| 26549995 | SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre, cross-sectional study. | Rep Pract Oncol Radiother | 2015 |
| 26156249 | Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy. | Strahlenther Onkol | 2015 |
| 26065609 | Correction to Lancet Oncol 2015; 16: 324. High-dose radiotherapy with shortterm or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. | Lancet Oncol | 2015 |
| 26065605 | Reporting of results in DART01/05 GICOR - Author's reply. | Lancet Oncol | 2015 |
| 26109913 | Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance. | Rep Pract Oncol Radiother | 2015 |
| 25702876 | High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. | Lancet Oncol | 2015 |
| 25524941 | HIF1A expression in localized prostate cancer treated with dose escalation radiation therapy. | Cancer Biomark | 2015 |
| 24682792 | Infrastructures, treatment modalities, and workload of radiation oncology departments in Spain with special attention to prostate cancer. | Clin Transl Oncol | 2014 |
| 24946957 | Predictive value of PAK6 and PSMB4 expression in patients with localized prostate cancer treated with dose-escalation radiation therapy and androgen deprivation therapy. | Urol Oncol | 2014 |
| 22855195 | Practice patterns in the management of prostate cancer in Spain: results from a national survey among radiation oncologists in 2009. | Clin Transl Oncol | 2013 |